Ферронал

Quick links to important sections

Ферронал

Treatment option: Pregnancy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ферронал

Property Description
Active ingredient Ferrous Gluconate (Железа глюконат)
Form Tablet (often film-coated tablet), Elixir
Pharmacological class Hematinic / Iron Preparation
Common purpose Iron replacement and support for oxygen transport
Origin Synthetic/Derived mineral salt

What Type of Medicine is Ферронал and What is it Made Of?

Ферронал is classified as a pharmaceutical preparation belonging to the Hematinic pharmacological class, a group of agents clinically recognized for their role in supporting blood component formation. The active ingredient is Ferrous Gluconate (Железа глюконат), and the medicine functions fundamentally as an Iron Preparation intended to provide essential mineral iron to the body.

The compound Ferrous Gluconate is a specific mineral salt, chemically defined as the Iron(II) salt combined with gluconic acid. This form is specifically manufactured to deliver bioavailable Elemental Iron (Fe²⁺) for systemic absorption. Pharmacological studies support the use of ferrous salts generally in correcting mineral deficiencies. Ферронал is characterized as a single product, focusing solely on the therapeutic action of this core iron source.


Form, Origin, and General Purpose

This preparation is categorized as a synthetic/derived compound, resulting from the chemical stabilization of the mineral iron with the organic component gluconic acid. This medicine is structured primarily for oral administration and is commonly available in versatile dosage forms, including the film-coated tablet or a liquid elixir, making it suitable for different patient preferences.

The general purpose of Ферронал is to stabilize and normalize the body’s iron status. The Ferrous Gluconate directly supports the synthesis of hemoglobin, which is the critical protein responsible for oxygen transport throughout the circulatory system. By facilitating robust hemoglobin formation, this essential iron replacement action is aimed at supporting overall vitality and function in all organ systems reliant on the efficient delivery of oxygen.

What side effects are possible with Ферронал?

Possible Side Effects and Safety Information

The official regulatory documents for oral iron preparations like Ferrous Gluconate classify the potential for adverse reactions primarily within the Gastrointestinal System. The safety profile is dominated by effects considered Common, with explicit warnings regarding signs of severe systemic reactions and the critical risk of accidental overdose, particularly in children.


Common and Expected Adverse Reactions

Adverse reactions most frequently listed in official labels are those involving the gastrointestinal tract. These effects are generally categorized as Common and may include constipation, diarrhea, nausea, vomiting, abdominal pain, or loss of appetite (anorexia). Changes to stool appearance are also commonly documented, specifically the occurrence of green-colored stools or darkening of stools, which is a general characteristic of iron preparations.


Serious Adverse Reactions and Safety Restrictions

Regulatory agencies require documentation of serious and potentially life-threatening reactions. Signs of severe complications include black or tarry stools (melena), bright red blood in stools, or vomiting blood (hematemesis). Severe systemic reactions may present as allergic reactions with signs such as hives or difficulty breathing.

  • Safety Restriction: The preparation is Contraindicated in patients with conditions involving iron overload, such as hemochromatosis or hemosiderosis, as well as in individuals with hemolytic anemia.
  • Pediatric Risk: A mandatory warning states that accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age.
  • Concomitant Safety: Official notes indicate that this product may interfere with the absorption of certain medicines, such as tetracycline antibiotics.

Overdose and Emergency Response

The official regulatory profile for Ферронал (Ferrous Gluconate) overdose emphasizes the risk of severe, multi-phased toxicity and the need for immediate emergency intervention.

Clinical Manifestations and Progression

Overdose typically presents first with severe gastrointestinal symptoms, including vomiting, abdominal pain, and bloody diarrhea. These initial symptoms may be followed by a transient period of apparent improvement before a severe relapse. Acute iron toxicity can rapidly progress to life-threatening conditions such as shock (circulatory collapse), profound metabolic acidosis, and CNS depression (drowsiness progressing to coma).

Severe Outcomes and Emergency Action

Delayed, life-threatening outcomes documented in official sources include severe liver damage ( hepatic necrosis), seizures, and intestinal scarring. Because of this progression, immediate medical attention is required for all suspected overdoses. It is mandatory to call a doctor or poison control center immediately if accidental ingestion occurs.

Pediatric Warning and Management

Official labeling emphasizes that accidental overdose of iron-containing products is a leading cause of fatal poisoning in children younger than 6 years. Urgent hospitalization is necessary for symptomatic patients or those with intentional ingestion.

Management procedures include the use of the specific chelation agent Desferrioxamine (Deferoxamine) as an antidote to bind systemic iron in severe toxicity. Treatment requires continuous hospital monitoring, including tracking vital signs and serial serum iron level assessments.

Therapeutic Uses of Ферронал

What Ферронал Treats: Main Uses and Benefits

Ферронал (Ferrous Gluconate) is generally used to address conditions characterized by systemic imbalance specifically related to low blood levels of iron and Iron Deficiency Anemia (IDA). This preparation is applied across domains where additional symptomatic support is needed. Treatment for low iron and resulting anemia may be part of supportive management through iron supplements.

The medication is commonly used to help manage clinical scenarios that present with persistent fatigue, generalized weakness, and symptoms that create noticeable physiological strain and pallor. It is considered relevant in conditions involving episodic or fluctuating manifestations, such as those caused by insufficient dietary intake, poor absorption, or ongoing losses. The product is also commonly used in clinical settings where the body’s iron requirement is significantly elevated, including during pregnancy and in women with persistent heavy menstrual bleeding.

The support provided may contribute to easing discomfort during periods of systemic imbalance. It helps address symptom clusters that interfere with daily functioning, assisting the patient with functional stability.

Quick Fact: Support for Fatigue Related to Systemic Imbalance The medication is relevant for easing symptoms related to systemic imbalance, assisting with the overall symptom load and contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. NIH MedlinePlus overview of Iron

Eligibility and Restrictions for Use

Official Eligibility Profile for Ферронал (Ferrous Gluconate)

Official regulatory documentation defines eligibility for Ferrous Gluconate based primarily on the patient’s iron status and clinical history.

Populations For Whom Use is Allowed

Ферронал is generally indicated for adults and children diagnosed with Iron Deficiency Anemia (IDA). Use is generally allowed and often recommended for the treatment and prophylaxis of iron deficiency in both pregnant and breastfeeding women.

Populations For Whom Use is Contraindicated

Use is contraindicated (must not be used) in patients with conditions involving iron overload, such as Hemochromatosis or Hemosiderosis. It is also prohibited in patients with anaemias other than iron-deficiency anemia (e.g., Hemolytic Anemia). The medication is contraindicated in individuals receiving repeated blood transfusions, or those with active peptic ulcer, ulcerative colitis, or regional enteritis.

Age-Related and Conditional Restrictions

There is a regulatory Warning concerning the risk of accidental fatal poisoning in children under 6 years of age. Use is not recommended for certain forms in the pediatric population. Caution is advised for patients with a history of peptic ulcer or existing inflammatory syndromes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ферронал (Ferrous Gluconate) has officially documented pharmacokinetic interactions that primarily alter the systemic exposure of co-administered medicines or the iron itself. Regulatory authorities classify these interactions as significant, necessitating procedural constraints on administration timing due to the risk of reduced therapeutic effect.

Co-administration with certain medicinal products, most notably Tetracycline and Quinolone antibiotics (such as Ciprofloxacin), results in a documented reduction in the systemic exposure of the antibiotic. This outcome is primarily attributed to chelation, where the iron forms an insoluble complex with the co-administered drug in the gastrointestinal tract. Similarly, co-administration with Levothyroxine or Biphosphonates leads to reduced absorption of these respective medicines.

Acid-reducing agents, including common Antacids or Proton Pump Inhibitors, may also reduce the absorption of Ferrous Gluconate by altering gastric pH.

To mitigate the risk of reduced effectiveness for the interacting agents, official regulatory labeling strictly requires mandatory separation of administration. The dose of Ferrous Gluconate must typically be spaced 2 to 4 hours apart from the interacting medicine.

Furthermore, specific dietary compounds also influence absorption. Phytates found in cereals, Tannins in tea and coffee, and high amounts of Calcium from supplements or dairy products are officially documented to significantly reduce iron absorption through complex formation.

Mechanism of Action

Mechanism of Action: Iron Substrate Restoration

Ферронал delivers the essential mineral Ferrous ion ( Fe^2+) as a direct building block for critical biological structures. The mechanism begins with the active transport of Fe^2+ across the intestinal epithelium via the Divalent Metal Transporter 1 ( DMT1), followed by controlled systemic release through the cellular iron exporter Ferroportin. This initial step provides the necessary substrate for subsequent molecular processes.

Once delivered to the bone marrow, the Fe^2+ is incorporated into the Protoporphyrin ring to form Heme, which is subsequently integrated into the Apo-Hemoglobin structure. This synthesis process creates new, functional Hemoglobin molecules, thereby increasing the oxygen-carrying capacity of the blood .

Beyond blood cell formation, the supplied Fe^2+ is an indispensable cofactor for iron-sulfur cluster enzymes, including cytochromes within mitochondria. Restoration of these key enzyme functions contributes to the maintenance of cellular respiration and ATP generation, which are foundational metabolic processes.

Dosage and Administration Information

How to Use Ферронал — Official Administration Guidelines

The medicine Ферронал (Ferrous Gluconate) is intended for oral administration only and is supplied in forms such as tablets and liquid elixir. Dosing is always calculated based on the elemental iron content, where a common 324 mg tablet delivers approximately 38 mg of elemental iron.


Official Dosing and Frequency

For adults undergoing therapeutic use, the regimen typically provides 114 mg to over 200 mg of elemental iron per day, and is often administered in divided doses (e.g., three to four times daily). Use for prevention or maintenance may involve lower daily elemental iron doses taken once daily. Pediatric administration requires weight-based calculations for elemental iron (e.g., 3 mg to 6 mg/ kg/ day for treatment), to be administered in divided amounts.


Administration Context and Duration

The tablets must be swallowed whole and are not to be crushed or chewed, a specific procedural instruction related to the form’s design. The medication is preferably taken on an empty stomach to maximize absorption, though it may be taken with food if necessary for digestive tolerance. Liquid forms must be diluted prior to ingestion. The full course of therapy is officially structured to continue for approximately three months after the normalization of hemoglobin levels to ensure the complete replenishment of the body's iron reserves. If a scheduled dose is missed, it is advised not to take a double dose at the subsequent interval.

Recent Clinical Evidence

Research evidence / Overview of studies for Ферронал

Evidence for Use in Treating Iron Deficiency Anemia (IDA) and Low Iron Status

Research has explored the use of the active ingredient in Ферронал (Ferrous Gluconate) as a preparation that was studied for use in individuals with Iron Deficiency Anemia (IDA) and general low iron status. These clinical evaluations include Randomized Controlled Trials (RCTs) and systematic reviews, which are used to track how iron preparations were evaluated in defined study groups.

Studies monitored changes in key Biomarkers of Iron Status. These outcomes primarily included measuring shifts in Hemoglobin (Hb) levels (a key protein marker), Serum Ferritin concentrations (a common iron storage marker), and Transferrin Saturation (TSAT). Research examined the impact on these markers over defined time intervals to observe measured changes in the observed populations. Many of these trials are comparative, meaning they were designed to evaluate this preparation against other forms of oral iron.

What remains unclear is the long-term durability of these changes. Follow-up durations were limited in many studies, meaning there is limited information for long-term outcomes on how effectively iron status is maintained after the study period ends.


Research on Use During Pregnancy and Other Contexts

Research has also examined the use of iron preparations for research examining iron status in high-risk groups. Specifically, this medicine was studied for use in pregnant women to examine the association between the preparation's use and iron levels and to monitor outcomes such as the risk of iron deficiency anemia at term. Researchers also examined the connection between maternal iron status and outcomes related to the newborn, such as low birth weight or preterm birth.

Evidence in Special Populations

Clinical research has included specific demographic groups to observe measured outcomes in specific demographic groups. The active ingredient was evaluated in toddlers and monitored in older adults who had been diagnosed with IDA.


What Is Still Uncertain and Research Gaps

The structural limitation is that many trials focus on comparative designs against other iron salts, meaning that large-scale trials against a placebo are less common. This leaves some uncertainty about the magnitude of the measured shifts in iron status markers for this specific formulation. Furthermore, follow-up durations were limited in many of the trials, and there is limited information for long-term outcomes on the sustained correction of iron deficiency. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Ферронал (FAQ)

Q: What happens if I miss a dose of Ферронал?

Regulatory documents covering the use of the preparation advise against taking a double dose at the subsequent interval if a scheduled dose is missed. This procedural instruction helps manage consistency in the treatment plan and prevents the risk of acute overdose.


Q: Is Ферронал considered safe to use during pregnancy, according to official sources?

Official documentation indicates that the preparation is generally acceptable and often recommended during pregnancy and lactation. This use is commonly associated with addressing iron deficiency in these specific populations.


Q: Do studies suggest any long-term effects associated with using Ферронал?

Regulatory guidance suggests that administration of iron preparations for longer than six months should generally be avoided. Use beyond six months is typically reserved for specific clinical situations, such as patients with continuous blood loss, to manage the risk of excess iron accumulation over time.


Q: Can Ферронал affect the absorption of other vitamins and minerals?

Yes, official documents note that the active ingredient may decrease the absorption of certain other minerals, specifically Manganese and Calcium. It may also interfere with the absorption of Vitamin E, and this is often discussed in the context of administration timing.


Q: Is it possible to take too much Ферронал accidentally?

Accidental overdose of iron-containing products is cited as a leading cause of fatal poisoning in children under six years of age. Overdose symptoms in adults can include severe gastrointestinal issues and a state of shock, and these warnings highlight the potential severity associated with excessive intake.


Q: Does current research compare Ферронал to placebo in terms of effectiveness themes?

Research overviews indicate that many clinical trials involving this active ingredient have focused on comparing it to other existing forms of iron. As a result, large-scale studies evaluating this preparation solely against a placebo are less common in the available research literature.


Q: Is the absorption of Ферронал influenced by whether you take it with or without food?

Label information notes that the medication is often taken on an empty stomach, which is intended to maximize the absorption of the elemental iron. However, official instructions permit taking it with food to reduce the likelihood of digestive side effects, which can often occur when first starting iron therapy.


Q: What patient populations are generally advised to use Ферронал with caution?

Caution is generally advised for patients with a history of certain gastrointestinal issues, specifically including peptic ulcer, ulcerative colitis, or regional enteritis. Caution is also recommended for individuals receiving frequent blood transfusions due to the potential risk of iron overload.


Q: Does taking Ферронал affect the results of any common lab tests?

The preparation is known to affect standard biomarkers of iron status that are measured in blood tests. These specific markers include Hemoglobin (Hb), Serum Ferritin, and Transferrin Saturation (TSAT), all of which are tracked to evaluate the body’s iron levels.


Q: Can Ферронал be used by people who are vegetarian or vegan?

While the active ingredient is a mineral salt, the inactive ingredients listed in the product's formulation may include components such as Shellac and White Wax. Individuals adhering to strict vegetarian or vegan diets often review the full list of inactive ingredients, as some components may be of non-vegan origin.


Q: What is the connection between Ферронал and energy levels?

The mechanism of action for the active ingredient is fundamentally linked to supporting energy levels in the body. It is essential for the synthesis of Hemoglobin, which facilitates oxygen transport, and it also supports core metabolic processes like cellular respiration and the generation of ATP (chemical energy).


Q: Are there any common food or drink items that may interact with Ферронал?

Yes, official warnings note that the absorption of the active ingredient may be significantly reduced by specific food items. These include cereals, eggs, dairy products (such as milk), coffee, and tea, often due to compounds like phytates and tannins.


Q: Does Ферронал interact with common over-the-counter pain relievers?

Regulatory documents specifically address interactions with acid-reducing agents like Antacids, which are often found in over-the-counter stomach and pain relief products. These agents should be taken separately from the iron preparation, usually spaced two hours apart, to avoid reduced absorption.


Q: Is there a specific time of day generally discussed for taking Ферронал?

Official instructions advise taking the preparation at the same time(s) each day to maintain regularity and consistency. However, there is no mandate for adult use to take it at a specific time, such as exclusively in the morning or at night.


Q: Does Ферронал require a prescription?

The specific preparation is often classified in regulatory listings as a Dietary Supplement or an over-the-counter product, depending on the country and formulation. This classification generally means it is available for purchase without a prescription.


Q: Is there any research on the use of Ферронал in pediatric populations?

Research has examined the use of the active ingredient in toddlers and in older children to address iron deficiency. Despite this research, a mandatory warning highlights the serious risk of accidental overdose and fatal poisoning in children under six years old.


Q: What ingredients are listed as inactive in Ферронал?

Inactive ingredients commonly listed in regulatory documents provide structural and coloring properties to the preparation. These compounds often include substances such as Colloidal Silicon Dioxide, Corn Starch, Talc, Stearic Acid, Sucrose, and various colorants.


Q: Does official information state that Ферронал can cause headaches?

Headaches are not consistently listed among the most common adverse reactions to the oral preparation, which typically include gastrointestinal issues. However, headaches are included in the overall, less frequent list of side effects reported during the product's use.


Q: What is the meaning of the number or strength listed on the Ферронал packaging?

The numbers on the packaging typically refer to two distinct values. The larger number represents the total milligram weight of the iron salt (Ferrous Gluconate), and the smaller number indicates the elemental iron, which is the actual amount of iron available for the body to absorb.


Q: Can people with kidney conditions use Ферронал?

Regulatory documents show that the oral preparation includes dosing information for use in adult patients with Anemia Associated with Chronic Renal Failure. Furthermore, the injectable form of iron gluconate is indicated for use in specific kidney conditions, though these are two different product forms.


Q: Can people with liver conditions typically use Ферронал?

Regulatory warnings indicate the need to consult a healthcare provider regarding any history of liver problems prior to using the preparation, as severe liver damage can be a potential, though rare, complication associated with iron overdose.


Q: What is the general difference between a supplement and a drug like Ферронал?

In some regulatory contexts, preparations containing the active ingredient are classified as a Dietary Supplement. This classification defines the product's intended use and the specific regulatory pathway it follows, differentiating it from a prescription drug, though both contain the active iron component.


Q: Does the manufacturer of Ферронал provide a patient information leaflet?

Official patient information is provided through regulatory agencies in detailed documents that function as the official labeling for the product. These documents are public summaries of product information for both patients and healthcare professionals.


Q: Is it normal to feel a metallic taste after taking Ферронал?

Yes, regulatory reviews of iron supplements commonly list a metallic taste as a potential and generally expected side effect. This sensation is typically associated with the oral dosage form of iron preparations.

How should Ферронал be stored and disposed of?

How to Store and Dispose of Ферронал (Ferrous Gluconate)

Official regulatory labeling dictates strict conditions for storing and disposing of this iron preparation.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep protected from light, excess heat, and moisture.
Container Keep in the original container and ensure it is tightly closed.
Handling Note Liquid forms (Elixir) must not be frozen.
Child Safety Keep out of the sight and reach of children and properly secure the child-resistant closure.

Disposal Instructions

Unused or expired medicine must not be flushed down the toilet or poured into a drain. Disposal must be conducted through an official drug take-back program or according to local environmental regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ферронал found in:

A-Z Index: